![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » SOUTH AFRICA'S ENALENI PLANS TO SUE LUPIN
SOUTH AFRICA'S ENALENI PLANS TO SUE LUPIN
October 19, 2005
South Africa's largest generic drug company Enaleni Pharmaceuticals is planning to sue Lupin the Rs 1,200 crore domestic pharma major for terminating a marketing right unilaterally in violation of an existing agreement. The Durban-based Enaleni is now all set to drag the Indian company to court on behalf of Specpharm and Westbury companies recently acquired by Enaleni. Specpharm and Westbury had a four-year agreement, which was signed in June 2002, to distribute Lupin's anti-TB drugs in South Africa and other African markets.
Sify (http://sify.com/finance/equity/fullstory.php?id=13966876)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct